But in the meantime, scroll down the page for a very brief sketch of some of the rhetorical applications of bullshit that you'll come across regularly in the biotechnology/drug development business. People like me wade through this stuff so you don't have to.
An impolite way of referring to novel compounds, apart from those very rare novel compounds that are genuinely first in class.
genuinely first in class
A very rare type of drug that is a novel compound but not a me-too drug.
positive trend toward efficacy
We didn't hit the endpoint, but the trial wasn't a complete bust - at least not for the purposes of this press release.
high placebo response
No, the drug really isn't as bad as that - it worked great in the lab.
Everyone's got one, so why shouldn't we?
partner of choice
We are so desperate for a deal that we'll jump through any combination of hoops to get one.
Maybe a combination of these two drugs will be more than the sum of its parts; then again, maybe it won't.
financial terms of the agreement were not disclosed
Some of the details are a tad embarrassing, and we'd like to keep our dignity intact.
emerging therapeutic paradigm [this is a newly emerging cliche]
Our CEO, who's a business major and generally likes to steer clear of the science, loves saying this at corporate presentations. It makes him sound authoritative.
newly emerging threat
Be afraid, be very afraid - and give us a generous dollop of research funding so we can have a closer look.
Someone, somewhere did some sort of trial on this and established something or other, so it's all scientific and above board. [particularly useful for people flogging cosmeceuticals & nutraceuticals]
a failed drug that you can add to skin cream
a failed drug that you can add to baby formula or dairy products